Perrigo Company PLC (PRGO)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 4,373,400 | 4,655,600 | 4,451,600 | 4,138,700 | 5,063,300 | 
| Receivables | US$ in thousands | — | — | — | — | — | 
| Receivables turnover | — | — | — | — | — | 
December 31, 2024 calculation
            Receivables turnover = Revenue ÷ Receivables
            = $4,373,400K ÷ $—K
            = —        
The data provided indicates that Perrigo Company PLC did not report any specific figures for receivables turnover for the years ending December 31, 2020 through December 31, 2024. As a result, it is not possible to analyze or interpret the receivables turnover ratio for Perrigo Company PLC based on the available information. The receivables turnover ratio is a key indicator of how efficiently a company is collecting payments from its customers, and without the necessary data, a comprehensive analysis of Perrigo's receivables turnover performance cannot be conducted at this time.
Peer comparison
Dec 31, 2024
Company name
                    Symbol
                    Receivables turnover
                Perrigo Company PLC
                            PRGO
                            —
                        Abbott Laboratories
                            ABT
                            —
                        AbbVie Inc
                            ABBV
                            —
                        ACADIA Pharmaceuticals Inc
                            ACAD
                            —
                        Alkermes Plc
                            ALKS
                            4.05
                        Amphastar P
                            AMPH
                            5.37
                        ANI Pharmaceuticals Inc
                            ANIP
                            —
                        Arcus Biosciences Inc
                            RCUS
                            51.60
                        Biomarin Pharmaceutical Inc
                            BMRN
                            4.31
                        Bristol-Myers Squibb Company
                            BMY
                            4.49
                        Catalyst Pharmaceuticals Inc
                            CPRX
                            —